Diagnostic utility of a p63/α-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate

Modern Pathology

Volumn 17, Issue 10, 2004, Pages 1180-1190

  Molinié, Vincent ^a   Fromont, Gaëlle ^b   Sibony, Mathilde ^c   Vieillefond, Annick ^d   Vassiliu, Viorel ^e   Cochand Priollet, Béatrix ^f   Hervé, Jean M ^a   Lebret, Thierry ^a   Baglin, Anne C ^a  

^a FOCH HOSPITAL   (France)

^b INSTITUT MUTUALISTE MONTSOURIS   (France)

^c HÔPITAL TENON   (France)

^d Hôpital Cochin ^*  (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f HÔPITAL LARIBOISIÈRE   (France)

Author keywords

methyl CoA racemase; ASAP; Immunohistochemistry; Prostate biopsy; Prostate cancer

Indexed keywords

34BETA E12 PROTEIN; ALPHA METHYL COENZYME A RACEMASE; CYTOKERATIN 5; CYTOKERATIN 6; PROTEIN; PROTEIN P63; RACEMASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ACINAR CELL; ADENOMA; ARTICLE; CANCER MIMIC; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY;

BIOPSY, NEEDLE; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATINS; MALE; PHOSPHOPROTEINS; PROSTATE; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; SENSITIVITY AND SPECIFICITY; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 4744371073     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800197     Document Type: Article

References (34)

1. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet 2003;361:1045-1053.
2. Shah RB, Zhou M, LeBlanc M, et al. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 2002;26:1161-1168.
3. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-1775.
4. Parsons JK, Gage WR, Nelson WG, et al. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 2001;58:619-624.
5. Beach R, Gown AM, De Peralta-Venturina MN, et al. p504s immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 2002;26:1588-1596.
6. Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000;60:1677-1682.
7. Luo JH. Gene expression alterations in human prostate cancer. Drugs Today (Barc) 2002;38:713-719.
8. Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002;62:2220-2226.
9. Iczkowski KA, Chen HM, Yang XJ, et al. Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy. Urology 2002;60:851-854.
10. Helpap B, Kollermann J, Oehler U. Limiting the diagnosis of atypical small glandular proliferations in needle biopsies of the prostate by the use of immunohistochemistry. J Pathol 2001;193:350-353.
11. Gown AM, Vogel AM. Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues. Am J Pathol 1984;114:309-321.
12. Varma M, Linden MD, Amin MB. Effect of formalin fixation and epitope retrieval techniques on antibody 34betaE12 immunostaining of prostatic tissues. Mod Pathol 1999;12:472-478.
13. Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989;13:389-396.
14. Iczkowski KA, Cheng L, Crawford BG, et al. Steam heat with an EDTA buffer and protease digestion optimizes immunohistochemical expression of basal cell-specific antikeratin 34betaE12 to discriminate cancer in prostatic epithelium. Mod Pathol 1999;12:1-4.
15. Abrahams NA, Ormsby AH, Brainard J. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology 2002;41:35-41.
16. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001;25:43-50.
17. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403-439.
18. Yang A, McKeon F. p63 and p73: p53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000;1:199-207.
19. Davis LD, Zhang W, Merseburger A, et al. p63 expression profile in normal and malignant prostate epithelial cells. Anticancer Res 2002;22:3819-3825.
20. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol 2002;15:1302-1308.
21. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (p504s) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol 2003;27:772-778.
22. Zhou M, Chinnaiyan AM, Kleer CG, et al. alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002;26:926-931.
23. Jiang Z, Woda BA, Rock KL, et al. p504s: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001;25:1397-1404.
24. Jiang Z, Fanger GR, Woda BA, et al. Expression of alpha-methylacyl-CoA racemase (p504s) in various malignant neoplasms and normal tissues: astudy of 761 cases. Hum Pathol 2003;34:792-796.
25. Jiang Z, Iczkowski KA, Woda BA, et al. p504s immunostaining boosts diagnostic resolution of 'suspicious' foci in prostatic needle biopsy specimens. Am J Clin Pathol 2004;121:99-107.
26. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol 2004;28:69-76.
27. Amery L, Fransen M, De Nys K, et al. Mitochondrial and peroxisomal targeting of 2-methylacyl-CoA racemase in humans. J Lipid Res 2000;41:1752-1759.
28. Evans AJ. alpha-Methylacyl CoA racemase (p504s): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol 2003;56:892-897.
29. Schmitz W, Albers C, Fingerhut R, et al. Purification and characterization of an alpha-methylacyl-CoA racemase from human liver. Eur J Biochem 1995;231:815-822.
30. Jiang Z, Wu CL, Woda BA, et al. p504s/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol 2002;26:1169-1174.
31. Leav I, McNeal JE, Ho SM, et al. alpha-Methylacyl-CoA racemase (p504s) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. Hum Pathol 2003;34:228-233.
32. Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-methylacyl-CoA racemase (p504s) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 2002;26:921-925.
33. Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-1670.
34. Luo J, Dunn TA, Ewing CM, et al. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003;57:134-139.